Wegovy-maker Novo Nordisk said on Wednesday it will sharpen its commercial focus and reduce costs, after a major profit warning and new CEO announcement last week wiped some $95 billion of value from the company’s stock.
Recent Posts
- Shopify Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts
- ADNOC Gas Announces Record Second Quarter Performance, Demonstrating Resilience in Lower Price Environment
- Hugel posts record first-half net sales exceeding KRW200 billion in H1 2025
- Eurocastle Releases First Half 2025 Financial Results, 2025 AGM Results and PDMR Dealing Notification
- 20% Upper Circuit: Microcap stock skyrockets after reporting 529% QoQ increase in net profits